Polish Stem Cell Company Bioceltix Advances Canine Osteoarthritis Treatment Through EMA Regulatory Process
Bioceltix, a Wrocław-based stem cell company, has submitted responses to regulatory questions from the European Medicines Agency (EMA) regarding its lead therapeutic candidate BCX-CM-J for canine osteoarthritis. This represents a key milestone in the drug registration process ahead of market approval.